Company Encyclopedia
View More
name
Lisata Therapeutics
LSTA.US
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
1.925 T
LSTA.USMarket value -Rank by Market Cap -/-

Financial Score

30/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking312/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-71.45%E
    • Profit Margin-1704.86%E
    • Gross Margin0.00%E
  • Growth ScoreD
    • Revenue YoY0.00%C
    • Net Profit YoY12.04%C
    • Total Assets YoY-43.04%E
    • Net Assets YoY-48.80%E
  • Cash ScoreD
    • Cash Flow Margin-5.87%D
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreA
    • Gearing Ratio21.32%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    First Berlin Equity Research Reiterates Buy Rating on Lisata Therapeutics With USD 15 Price Target

    First Berlin Equity Research has reiterated its "Buy" rating for Lisata Therapeutics, setting a 12-month price target of $15 per share. Analyst Christian Orquera noted that Lisata's performance exceeded expectations due to reduced operational expenses and disciplined R&D spending. The company has strong cash reserves, supporting operations into Q1 2027, and progress in its certepetide platform. Further milestones could lead to a stock re-rating.

    Reuters·
    US
    LSTA
    -1.02%
    Reuters·
    US
    LSTA
    -1.02%

    Lisata Therapeutics’ Earnings Call: Progress Amid Challenges

    Lisata Therapeutics held its Q3 earnings call, revealing progress in clinical programs and strategic partnerships, but facing challenges in securing capital for Phase III trials. Highlights include a strategic alliance with GATC Health for drug discovery, a global license agreement with Catalent, and positive preliminary results from the Phase IIb ASCEND trial. The company reduced operating expenses by 17.3% and has a cash runway into 2027. However, it acknowledged the need for additional funds and faced limited stock market response despite positive developments.

    Tip Ranks·
    US
    LSTA
    -1.02%
    Tip Ranks·
    US
    LSTA
    -1.02%

    Lisata outlines Phase III certepetide trial preparations and targets milestone-rich 2026 amid expanded alliances

    Lisata Therapeutics (LSTA) CEO David Mazzo discussed the company's Phase III certepetide trial preparations during the Q3 2025 earnings call. He emphasized several development milestones, including positive preliminary results from the ASCEND, iLSTA, and CENDIFOX trials. The company aims for a milestone-rich 2026, supported by expanded alliances.

    MSN·
    US
    LSTA
    -1.02%
    MSN·
    US
    LSTA
    -1.02%

    Lisata Therapeutics Q3 net loss narrows to $4.2 mln

    Lisata Therapeutics reported a Q3 net loss of $4.2 million, down from $4.9 million year-over-year. Operating expenses decreased by 17.3% to $4.4 million. The company projects its cash reserves will fund operations into Q1 2027, with no debt. Analysts maintain a "buy" rating, with a median 12-month price target of $15.00, representing an 84.4% upside from its recent closing price of $2.34.

    Reuters·
    US
    LSTA
    -1.02%
    Reuters·
    US
    LSTA
    -1.02%

    Lisata Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    LSTA
    -1.02%
    LB filings·
    US
    LSTA
    -1.02%
    © 2025 Longbridge｜Disclaimer